|Table of Contents|

Research progress of TERT gene in susceptibility and prognosis of non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 01
Page:
193-196
Research Field:
Publishing date:

Info

Title:
Research progress of TERT gene in susceptibility and prognosis of non-small cell lung cancer
Author(s):
YANG Liu1; 2; CAI Jun1
1.First Affiliated Hospital of Yangzte University,Hubei Jingzhou 434023,China;2.Gong An County People's Hospital,Hubei Jingzhou 434300,China.
Keywords:
non-small cell lung cancer(NSCLC); TERT promoter mutation; telomerase reverse transcriptase; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.01.037
Abstract:
Lung cancer is one of the most common malignant tumors in the world and has remained the most common cause of cancer death in recent years.According to histological classification,about 85% of lung cancer patients are non-small cell lung cancer(NSCLC).Its poor prognosis is attributed to late diagnosis,high risk of recurrence and drug resistance.Telomerase is the key enzyme for cell survival.It can maintain the length of telomeres and make cells have the potential for unlimited proliferation and immortalization.The telomerase reverse transcriptase(TERT) gene encodes the telomerase reverse transcriptase,the telomerase catalytic subunit,which activates telomerase and enables carcinogenesis.The TERT promoter mutation has been shown to be a novel genetic mechanism for telomerase activation and exists in a variety of human tumors.The occurrence of human lung cancer is related to the activation of telomerase and the damage of telomeres.Moreover,TERT gene polymorphism is associated with susceptibility and prognosis of NSCLC.In this review，we briefly summarize the studies on TERT promoter mutation and TERT polymorphism in NSCLC,as well as its relationship with prognosis of NSCLC and the prospect of targeted therapy in the clinical practice.

References:

［1］MEENA J,RUDOLPH KL,GUNES C.Telomere dysfunction,chromosomal instability and cancer［J］.Recent Results Cancer Res,2015,200:61-79.
［2］NGUYEN T.Structural biology of human telomerase:Progress and prospects［J］.Biochem Soc Trans,2021,49(5):1927-1939.
［3］YUAN X,DAI M,XU D.Telomere-related markers for cancer［J］.Curr Top Med Chem,2020,20(6):410-432.
［4］YUAN X,LARSSON C,XU D.Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer:Old actors and new players［J］.Oncogene,2019,38(34):6172-6183.
［5］DAN J,ZHOU Z,WANG F,et al.Zscan4 contributes to telomere maintenance in telomerase-deficient late generation mouse ESCs and human ALT cancer cells［J］.Cells,2022,11(3):456.
［6］PESTANA A,VINAGRE J,SPBRINHO-SIMOES M,et al.TERT biology and function in cancer:Beyond immortalisation［J］.J Mol Endocrinol,2017,58(2):R129-R146.
［7］SHAY JW,WRIGHT WE.Telomeres and telomerase:Three decades of progress［J］.Nat Rev Genet,2019,20(5):299-309.
［8］GUO W,LU J,DAI M,et al.Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers［J］.Oncotarget,2014,5(19):9349-9361.
［9］POOS AM,SCHROEDER C,JAISHANKAR N,et al.PITX1 is a regulator of TERT expression in prostate cancer with prognostic power［J］.Cancers(Basel),2022,14(5):1267.
［10］BODNAR AG,OUELLETTE M,FROLKIS M,et al.Extension of life-span by introduction of telomerase into normal human cells［J］.Science,1998,279(5349):349-352.
［11］BRYCE LA,MORRISON N,HOARE SF,et al.Mapping of the gene for the human telomerase reverse transcriptase,hTERT,to chromosome 5p15.33 by fluorescence in situ hybridization［J］.Neoplasia,2000,2(3):197-201.
［12］SAHIN B,KATAR S,SAHIN SA,et al.Influence of human telomerase reverse transcriptase mutation on the aggressiveness and recurrence in meningiomas［J］.Cureus,2021,13(5):e15342.
［13］KIM W,LUDLOW AT,MIN J,et al.Regulation of the human telomerase gene TERT by telomere position effect-over long distances(TPE-OLD):Implications for aging and cancer［J］.PLoS Biol,2016,14(12):e2000016.
［14］COLEBATCH AJ,DOBROVIC A,COOPER WA.TERT gene:Its function and dysregulation in cancer［J］.J Clin Pathol,2019,72(4):281-284.
［15］CUKUSIC A,SKROBOT VN,SOPTA M,et al.Telomerase regulation at the crossroads of cell fate［J］.Cytogenet Genome Res,2008,122(3-4):263-272.
［16］VENUTI A,ROMERO-MEDINA MC,MELITA G,et al.Lyon IARC polyomavirus displays transforming activities in primary human cells［J］.J Virol,2022,96(14):e206121.
［17］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［18］CAO W,CHEN H D,YU YW,et al.Changing profiles of cancer burden worldwide and in China:A secondary analysis of the global cancer statistics 2020［J］.Chin Med J(Engl),2021,134(7):783-791.
［19］LU S,YU U,YANG Y,et al.Retrospect and prospect for lung cancer in China:Clinical advances of immune checkpoint inhibitors［J］.Oncologist,2019,24(Suppl 1):S21-S30.
［20］KAWAI T,HIROI S,NAKANISHI K,et al.Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung［J］.Am J Clin Pathol,2007,127(2):254-262.
［21］JI Z,LI Y,XIANG C,et al.TERT-rs33963617 and CLPTM1L-rs77518573 reduce the risk of non-small cell lung cancer in Chinese population［J］.Gene,2020,731:144357.
［22］BARTHEL FP,WEI W,TANG M,et al.Systematic analysis of telomere length and somatic alterations in 31 cancer types［J］.Nat Genet,2017,49(3):349-357.
［23］YAGYU T,OHIRA T,SHIMIZU R,et al.Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer［J］.Sci Rep,2021,11(1):15355.
［24］BARGER CJ,SUWALA AK,SOCZEK KM,et al.Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer［J］.Nat Commun,2022,13(1):5430.
［25］GRIEWANK KG,MURALI R,SCHILLING B,et al.TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma［J］.PLoS One,2013,8(11):e80354.
［26］JUNG SJ,KIM DS,PARK WJ,et al.Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer［J］.Oncol Lett,2017,14(2):1609-1614.
［27］CHIBA K,JOHNSON JZ,VOGAN JM,et al.Cancer-associated TERT promoter mutations abrogate telomerase silencing［J］.Elife,2015,4:e07918.
［28］LI C,WU S,WANG H,et al.The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer［J］.Oncotarget,2015,6(23):19542-19551.
［29］LI C,HAO L,LI Y,et al.Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer［J］.PLoS One,2014,9(9):e107276.
［30］MA X,GONG R,WANG R,et al.Recurrent TERT promoter mutations in non-small cell lung cancers［J］.Lung Cancer,2014,86(3):369-373.
［31］YUAN P,CAO JL,ABUDUWUFUER A,et al.Clinical characteristics and prognostic significance of TERT promoter mutations in cancer:A cohort study and a Meta-analysis［J］.PLoS One,2016,11(1):e146803.
［32］ISLAMI F,GODING SA,MILLER KD,et al.Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States［J］.CA Cancer J Clin,2018,68(1):31-54.
［33］TAN AC,TAN D.Targeted therapies for lung cancer patients with oncogenic driver molecular alterations［J］.J Clin Oncol,2022,40(6):611-625.
［34］WANG Y,BRODERICK P,MATAKIDOU A,et al.Role of 5p15.33(TERT-CLPTM1L),6p21.33 and 15q25.1(CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers［J］.Carcinogenesis,2010,31(2):234-238.
［35］LI Y,XIANG C,SHEN N,et al.Functional polymorphisms on chromosome 5p15.33 disturb telomere biology and confer the risk of non-small cell lung cancer in Chinese population［J］.Mol Carcinog,2019,58(6):913-921.
［36］WANG F,FU P,PANG Y,et al.TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma［J］.Tumour Biol,2014,35(5):4667-4672.
［37］WEI R,CAO L,PU H,et al.TERT polymorphism rs2736100-C is associated with EGFR mutation-positive non-small cell lung cancer［J］.Clin Cancer Res,2015,21(22):5173-5180.
［38］GHOSH A,SAGINC G,LEOW SC,et al.Telomerase directly regulates NF-kappaB-dependent transcription［J］.Nat Cell Biol,2012,14(12):1270-1281.
［39］LI C,WANG X,LI Y,et al.Genetic polymorphisms in the TERT gene and susceptibility to non-small cell lung cancer in a Chinese Han population［J］.Cancer Manag Res,2018,10:1487-1495.
［40］YUAN P,HUANG S,BAO FC,et al.Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation［J］.Eur J Cancer,2019,120:10-19.
［41］LI X,XU X,FANG J,et al.Rs2853677 modulates Snail1 binding to the TERT enhancer and affects lung adenocarcinoma susceptibility［J］.Oncotarget,2016,7(25):37825-37838.
［42］SONG YS,LIM JA,CHOI H,et al.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients［J］.Cancer,2016,122(9):1370-1379.
［43］LIU W,YIN Y,WANG J,et al.Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC［J］.Oncotarget,2017,8(1):179-190.
［44］LIN C,QIN Y,ZHANG H,et al.EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in nonsmall cell lung cancer cells［J］.Oncol Rep,2018,40(1):29-38.

Memo

Memo:
-
Last Update: 2023-11-30